Ascentage's lisaftoclax accepted for priority review in China

20 November 2024

Ascentage Pharma (HKEX: 6855) will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme.

The oral small-molecule inhibitor, which is being evaluated in 19 clinical trials worldwide, works by selectively blocking the BCL-2 protein, which plays a critical role in cancer cells evading apoptosis.

If approved, lisaftoclax could become the first BCL-2 inhibitor developed in China and the second globally. The NDA is based on a registrational Phase II study testing the therapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical